<DOC>
	<DOCNO>NCT02713295</DOCNO>
	<brief_summary>This study estimate treatment goal achievement rate , depict implementation Progressive Psoriasis Initiative ( PPI ) recommendation regard treatment modification transition , assess patient adherence persistence adalimumab therapy routine clinical practice Greece .</brief_summary>
	<brief_title>A Study Provide Real-world Evidence Treatment Goal Achievement Rate , Adherence Utilization Patterns Adalimumab Patients With Moderate Severe Plaque Psoriasis Greece</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Clinical diagnosis plaque psoriasis least 6 month , moderate severe disease course time adalimumab treatment onset , define Body Surface Area ( BSA ) &gt; 10 PASI &gt; 10 DLQI &gt; 10 Patients decision prescribe therapy adalimumab ( HumiraÂ® ) accord locally approve summary product characteristic ( SmPC ) already take prior enrolment study clearly separate physician 's decision include patient current study Patients available Psoriasis Area Severity Index ( PASI ) Dermatology Life Quality Index ( DLQI ) score start adalimumab treatment Patients able willing provide write informed consent comply requirement study protocol Patients sign informed consent document Patients nonplaque form psoriasis ( e.g. , erythrodermic , guttate , pustular ) Patients treatment adalimumab initiate 2 week prior enrolment study Patients meet contraindication administration study drug accord late version locally approve SmPC Patients previously expose adalimumab unless period least 6 month last dose elapse Patients currently receive treatment investigational drug/device/intervention receive investigational product within 1 month 5 halflives investigational agent ( whichever longer ) commencement therapy adalimumab .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Moderate Plaque Psoriasis</keyword>
	<keyword>Plaque Psoriasis</keyword>
	<keyword>Severe Plaque Psoriasis</keyword>
</DOC>